256 related articles for article (PubMed ID: 37219615)
1. Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC).
Ashique S; Garg A; Mishra N; Raina N; Ming LC; Tulli HS; Behl T; Rani R; Gupta M
Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):2769-2792. PubMed ID: 37219615
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
4. Redox-responsive nano-carriers as tumor-targeted drug delivery systems.
Raza A; Hayat U; Rasheed T; Bilal M; Iqbal HMN
Eur J Med Chem; 2018 Sep; 157():705-715. PubMed ID: 30138802
[TBL] [Abstract][Full Text] [Related]
5. Near-infrared/pH dual-responsive nanocomplexes for targeted imaging and chemo/gene/photothermal tri-therapies of non-small cell lung cancer.
Li Z; Zhu L; Liu W; Zheng Y; Li X; Ye J; Li B; Chen H; Gao Y
Acta Biomater; 2020 Apr; 107():242-259. PubMed ID: 32151700
[TBL] [Abstract][Full Text] [Related]
6. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
[TBL] [Abstract][Full Text] [Related]
7. Development of dual-targeted nano-dandelion based on an oligomeric hyaluronic acid polymer targeting tumor-associated macrophages for combination therapy of non-small cell lung cancer.
Wang B; Zhang W; Zhou X; Liu M; Hou X; Cheng Z; Chen D
Drug Deliv; 2019 Dec; 26(1):1265-1279. PubMed ID: 31777307
[TBL] [Abstract][Full Text] [Related]
8. Emerging Strategies in Stimuli-Responsive Nanocarriers as the Drug Delivery System for Enhanced Cancer Therapy.
Saravanakumar K; Hu X; Ali DM; Wang MH
Curr Pharm Des; 2019; 25(24):2609-2625. PubMed ID: 31603055
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Liang Y; Tian B; Zhang J; Li K; Wang L; Han J; Wu Z
Int J Nanomedicine; 2017; 12():1699-1715. PubMed ID: 28280336
[TBL] [Abstract][Full Text] [Related]
10. Organ-restricted delivery through stimuli-responsive nanocarriers for lung cancer therapy.
Dinakar YH; Karole A; Parvez S; Jain V; Mudavath SL
Life Sci; 2022 Dec; 310():121133. PubMed ID: 36306866
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Review on Nanoparticles as a Targeted Delivery System for the Treatment of Lung Cancer.
Gupta T; Varanwal A; Nema P; Soni S; Iyer AK; Das R; Soni V; Kashaw SK
Anticancer Agents Med Chem; 2024; 24(3):157-168. PubMed ID: 38013441
[TBL] [Abstract][Full Text] [Related]
12. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
13. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
14. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Song Y; Zhou B; Du X; Wang Y; Zhang J; Ai Y; Xia Z; Zhao G
Biomed Pharmacother; 2020 May; 125():109561. PubMed ID: 32106385
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine for Treatment of Lung Cancer.
Hussain S
Adv Exp Med Biol; 2016; 890():137-47. PubMed ID: 26703803
[TBL] [Abstract][Full Text] [Related]
16. Nanocarrier-Mediated Drug Delivery via Inhalational Route for Lung Cancer Therapy: A Systematic and Updated Review.
Ara N; Hafeez A
AAPS PharmSciTech; 2024 Feb; 25(3):47. PubMed ID: 38424367
[TBL] [Abstract][Full Text] [Related]
17. Lipid-coated polymeric nanoparticles for cancer drug delivery.
Krishnamurthy S; Vaiyapuri R; Zhang L; Chan JM
Biomater Sci; 2015 Jul; 3(7):923-36. PubMed ID: 26221931
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier.
Wang X; Mao W; Wang Z; Li X; Xiong Y; Lu H; Wang X; Yin H; Cao X; Xin H
Int J Nanomedicine; 2020; 15():5491-5501. PubMed ID: 32848385
[TBL] [Abstract][Full Text] [Related]
19. Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.
Zhang W; Li C; Shen C; Liu Y; Zhao X; Liu Y; Zou D; Gao Z; Yue C
Drug Deliv; 2016 Sep; 23(7):2575-2580. PubMed ID: 26056720
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
Shukla SK; Kulkarni NS; Farrales P; Kanabar DD; Parvathaneni V; Kunda NK; Muth A; Gupta V
Pharm Res; 2020 Mar; 37(3):67. PubMed ID: 32166411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
